SOX11 and Survival in Ovarian Cancer
Author Information
Author(s): Sernbo Sandra, Gustavsson Elin, Brennan Donal J, Gallagher William M, Rexhepaj Elton, Rydnert Frida, Jirström Karin, Borrebaeck Carl AK, Ek Sara
Primary Institution: Lund University
Hypothesis
The expression of SOX11 is associated with improved survival in high-grade epithelial ovarian cancers.
Conclusion
SOX11 is a prognostic marker for high-grade ovarian cancer, and its re-expression may be targeted with epigenetic drugs.
Supporting Evidence
- SOX11 expression was associated with improved survival in high-grade EOC.
- Demethylation of SOX11 promoter led to re-expression of SOX11 in EOC cell lines.
- Overexpression of SOX11 in EOC cell lines resulted in reduced cell proliferation.
Takeaway
SOX11 helps patients with a type of ovarian cancer live longer, and doctors might use special drugs to turn it back on in tumors that have it turned off.
Methodology
The study compared SOX11 expression and clinicopathological data using χ2 test, Kaplan-Meier analysis, and log rank test in a cohort of 154 cases of primary invasive EOC.
Limitations
The study suggests a need for larger cohorts to confirm the independent prognostic relevance of SOX11 in endometrioid cancer.
Participant Demographics
The cohort included 154 cases of primary invasive epithelial ovarian cancer with various histological subtypes.
Statistical Information
P-Value
0.047
Statistical Significance
p = 0.047
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website